Sino Biopharmaceutical Stock (OTC: SBHMY)

Latest news for Sino Biopharmaceutical (OTC:SBHMY) Stock

Sino Biopharmaceutical

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

AACS

AAON

AAUKF

ACDSF

ACGL

ACIA

ACLS

ADBE

ADSK

ADYYF

AFFY

AFGC

AIQUY

AJMPF

AKAM

ALCO

ALFVY

ALLE

ALLT

AMADY

AMAT

AMBC

AMED

AMIGF

AMRC

AMWD

ANCUF

ANSLY

ANSS

AOMFF

AOMOY

APAM

APPF

ARBV

ARES

ASAZF

ASAZY

ASHTY

ASPN

ASYS

ATCMF

ATLC

ATRC

ATVI

ATZAF

AUDC

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

BAESY

BANF

BASI

BATRA

BCPC

BCUCY

BEVFF

BF-A

BF-B

BHOOY

BIOS

BKRKY

BLDP

BLSP

BMDPY

BORT

BPOP

BRK-A

BRK-B

Stocks That Hit 52-Week Highs On Friday

AJRD

ATUS

BAND

BENZF

BKRRF

CDAY

CDSG

CINF

COLD

CVTV

DPMLF

DXCM

ELRFF

ENTMF

EVRG

EXPGF

FFHL

FORTY

GNRC

GTBDF

HEBT

HUBS

INTU

JBSS

LGHT

LOPE

LPCN

LPSN

MKTX

NXRT

NXTC

PBHG

PFMS

PFSI

PNCKF

PODD

PTPIF

QIWI

SBAC

SBHMY

SPMYY

SWCH

SWPRF

TMHC

TOELY

TRXD

TSKFF

USFD

XNGSY

ZLAB

CSPCY

RUMOF

CGJTF

MGPPF

HLNFF

ECNRF

SINO BIOPHARM UNSP/ADR by Sino Biopharmaceutical Ltd.

Sino Biopharmaceutical Ltd

Goldman Sachs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) has outperformed the market over the past 5 years by 6.87% on an annualized basis producing an average annual return of 19.87%. Currently, Goldman Sachs Gr has a market capitalization of $180.39 billion. 
Buying $100 In GS: If an investor had bought $100 of GS stock 5 years ago, it would be worth $246.87 today based on a price of $571.21 for GS at the time of writing.
<h3>Goldman Sachs Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734994828_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Goldman Sachs Gr 5 Years Ago Would Be Worth Today

WIIM

NEUE

NeueHealth shares are trading higher after the company announced it has entered into an definitive merger to be acquired for $7.33 per share.

NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEUE#NYSE">NEUE</a>), the value-driven healthcare company, today announced that it has entered into a definitive merger agreement pursuant to which the Company will be acquired by an affiliate of New Enterprise Associates ("NEA") at an enterprise value of approximately $1.3 billion. Upon completion of the transaction, NeueHealth will become a privately held company with the flexibility and resources to continue advancing its value-driven, consumer-centric care model.
Under the terms of the merger agreement, holders of NeueHealth common stock (other than shares that will be rolled over and certain excluded shares) will receive $7.33 per share in cash, which represents a premium of approximately 70% over the closing price of NeueHealth common stock on December 23, 2024. Certain stockholders of NeueHeath, including NEA and 12 existing NeueHealth investors (which collectively hold all of the outstanding shares of NeueHealth preferred stock), have entered into rollover agreements pursuant to which such stockholders will continue their investments by exchanging their shares of NeueHealth common stock and/or preferred stock for newly issued equity interests in the privately held company, and the Company's existing secured loan facility with Hercules Capital, Inc. will remain in place.
NeueHealth's executive leadership team will continue in their roles upon completion of the transaction and intends to roll over 100% of their equity interests for newly issued equity interests in the privately held company.

NeueHealth  Entered Into A Definitive Merger Agreement To Be Acquired By An Affiliate Of New Enterprise Associates At An Enterprise Value Of ~$1.3B, Or $7.33/Share In Cash

INSW

International Seaways shares are trading higher after it was announced that the company will join the S&P SmallCap 600 on December 30, 2024.

International Seaways Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSW#NYSE">INSW</a>) will replace Consolidated Communications Holdings (NASD: CNSL) in the S&amp;P SmallCap 600 effective prior to the opening of trading on Monday, December 30. Searchlight Capital Partners and British Columbia Investment Management Corporation (BCI) are acquiring Consolidated Communications in a deal expected to be completed soon, pending final closing conditions.

International Seaways To Join S&P SmallCap 600 On Monday, December 30, 2024

CBRE Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) has outperformed the market over the past 5 years by 3.45% on an annualized basis producing an average annual return of 16.45%. Currently, CBRE Group has a market capitalization of $39.94 billion. 
Buying $100 In CBRE: If an investor had bought $100 of CBRE stock 5 years ago, it would be worth $212.97 today based on a price of $130.51 for CBRE at the time of writing.
<h3>CBRE Group's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734993914_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBRE

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

CREV

Carbon Revolution shares are trading higher after the company announced it has reached an agreement with OIC for a further $25 million in financing to support the ongoing liquidity of the business.

Carbon Revolution plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>) (the "Company"), a Tier 1 OEM supplier and the leading global manufacturer of lightweight advanced technology automotive carbon fiber wheels, today announced that it has reached an agreement with Orion Infrastructure Capital ("OIC") for a further US$25 million financing, which will be released in five tranches, each equal to US$5 million, subject to satisfying certain release conditions. In connection with the release of each of the five tranches of US$5 million, the Company will issue to OIC and the lenders under the US$60 million PIUS loan entered into in May 2023 ("Existing Noteholders"), penny warrants to purchase an aggregate number of shares equal to 5.0% of the Company's shares outstanding.

Financing

Carbon Revolution Has Reached An Agreement With Orion Infrastructure Capital For A Further $25M Financing, Which Will Be Released In 5 Tranches, Each Equal To $5M

CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) has outperformed the market over the past 5 years by 36.5% on an annualized basis producing an average annual return of 49.5%. Currently, CrowdStrike Holdings has a market capitalization of $88.93 billion. 
Buying $1000 In CRWD: If an investor had bought $1000 of CRWD stock 5 years ago, it would be worth $7,301.27 today based on a price of $361.06 for CRWD at the time of writing.
<h3>CrowdStrike Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734993015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRWD

$1000 Invested In CrowdStrike Holdings 5 Years Ago Would Be Worth This Much Today

Streaming giant Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) is set to release the highly anticipated second season of "Squid Game" on Dec. 26, adding to an exciting month with its first live NFL games <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41123711/netflix-stock-could-get-boost-from-nfl-games-squid-game-season-2-analyst-says-conte">on Christmas Day.</a>
A Benzinga reader poll shows the second season might face more of an uphill battle for viewers compared to the first season in 2021.
What Happened: Released in September 2021, "Squid Game" <a href="https://www.benzinga.com/general/entertainment/24/12/42305013/squid-game-season-2-includes-new-games-contestant-with-a-crypto-background-revenge-factor-political-overtones">shattered viewership records </a>for Netflix with 1.65 billion hours watched in the first four weeks of availability.
The series became a massive hit and pop culture phenomenon and fans have eagerly been awaiting a second season.
Netflix will premiere all seven episodes of the second season on Dec. 26, beginning at 3 a.m. ET. Benzinga recently polled readers to see how eager people are to watch the new season.
"Will you be watching ‘Squid Game' season 2?" Benzinga asked.
The results were:
<ul>
<li>No, I don't plan to watch: 70%</li>
<li>Yes, I'll binge-watch the entire season when it's out: 21%</li>
<li>Yes, I'll watch each episode as soon as I can: 9%</li>
</ul>
The poll found that Benzinga readers are less excited about the second season compared to the interest generated by the first season.
The day-after-Christmas release could be a double-edged sword for Netflix. While the timing benefits from people being off work, it also coincides with family gatherings that might limit viewership.
Netflix will <a href="https://www.benzinga.com/general/entertainment/24/12/42657482/mrbeast-dominates-prime-video-how-youtuber-could-help-amazon-boost-streaming-presence">also be competing</a> with MrBeast's "Beast Games," a record-breaking game show on Amazon.com's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Prime Video. &#8220;Beast Games&#8221; released its first two episodes on Dec. 19 with a third episode coming on Dec. 26. The show features elements similar to the contests featured in &#8220;Squid Game.&#8221;
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/12/42563662/streamers-max-paramount-won-november-heres-why-analyst-expects-netflix-amazon-to-win-december">Streamers Max, Paramount+ Won November: Here&#8217;s Why Analyst Expects Netflix, Amazon To Win December</a>
What's Next: The second season of "Squid Game" will bring back several cast members from the first season. The new season has already been <a href="https://www.benzinga.com/general/entertainment/24/12/42395178/golden-globes-2025-nominations-netflix-scores-nods-for-emilia-perez-and-squid-game-comcast-lands-4-wicked-noms">nominated for a Golden Globe</a> and could become a favorite on the awards circuit, given more hype around the show this time.
Returning for the second season is the winner of the game in the first season, Seong Gi-hun (aka Player 456), portrayed on screen by&nbsp;Lee Jung-jae.&nbsp;Director and writer&nbsp;Hwang Dong-Hyuk&nbsp;also returns for the second season.
The second season features new characters and revolves around Gi-hun, who returns to the game three years after the competition to search for the people behind it and shut it down for good, as reported by <a href="https://deadline.com/2024/12/squid-game-season-2-explained-hwang-dong-hyuk-lee-jung-jae-1236189235/" target="_blank" rel="noreferrer noopener">Deadline</a>.
This time, characters competing for the prize include a former cryptocurrency influencer who loses a large amount of money for his subscribers and himself. The crypto influencer becomes a fugitive before joining the Squid Game competition, according to the report.
Another one of the 400-plus contestants in the games is a woman who made bad investments following the advice of the same cryptocurrency influencer taking part in the games.
Following the second season, a third and final season of the hit show will be released in 2025. Director Hwang said the second and third seasons were written at the same time and both were produced simultaneously. The third season is currently in the post-production process, the director said.
The first season of "Squid Game" has been watched by a total of 330 million viewers and a total of 2.8 billion hours have been streamed since the release, as reported by <a href="https://variety.com/2024/tv/news/squid-game-viewers-netflix-seoul-experience-1236232449/">Variety</a>. The overall metrics and the first four weeks&#8217; totals for the second season will be used to compare the success of the newest season.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42653325/exclusive-netflix-to-have-merry-christmas-with-nfl-games-will-viewers-tune-in-60-say">EXCLUSIVE: Netflix To Have Merry Christmas With NFL Games, Will Viewers Tune In? 60% Say…</a></li>
</ul>
The study was conducted by Benzinga from Dec. 18 through Dec. 19, 2024, and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 145 adults.
Photo by DANIEL CONSTANTE on Shutterstock

Entertainment

Exclusives

AMZN

NFLX

EXCLUSIVE: 'Squid Game' Broke Netflix Records, Will Viewers Watch Season 2? 70% Of Benzinga Readers Say…

American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) has outperformed the market over the past 20 years by 3.99% on an annualized basis producing an average annual return of 12.27%. Currently, American Tower has a market capitalization of $87.84 billion. 
Buying $1000 In AMT: If an investor had bought $1000 of AMT stock 20 years ago, it would be worth $10,289.06 today based on a price of $187.97 for AMT at the time of writing.
<h3>American Tower's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734992108_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In American Tower 20 Years Ago Would Be Worth This Much Today

Four Corners Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCPT#NYSE">FCPT</a>), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties ("FCPT" or the "Company"), is pleased to announce the acquisition of a National Veterinary Associates property for $3.5 million. The property is located in Connecticut and is corporate-operated under a new long-term, triple net lease with annual rent bumps. The transaction was priced at a cap rate in range with previous FCPT transactions.

FCPT

FCPT Announces Acquisition Of A National Veterinary Associates Property For $3.5M

Wilmington, Del., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) announced today that it has signed a definitive agreement to sell its Avoca business to Mane. The transaction is expected to close in the calendar first quarter 2025, subject to the satisfaction of customary closing conditions.
Ashland's Avoca business supplies Sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin.&nbsp; The Avoca business line represents the last entity from Ashland's previous acquisition of Pharmachem.

Asset Sales

Ashland Signs Definitive Agreement To Sell Avoca Business To Mane; Expected To Close In Q1 2025; No Financial Terms Disclosed

KORE Group Holdings, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KORE#NYSE">KORE</a>)&nbsp;("KORE" or the "Company"), the global pure-play Internet of Things ("IoT") hyperscaler and provider of IoT Connectivity, Solutions, and Analytics, today announced it has received notification (the "Acceptance Letter") from the New York Stock Exchange (the "NYSE") that the NYSE has accepted the Company's previously-submitted plan (the "Plan") to regain compliance with the NYSE's continued listing standards set forth in Section 802.01B of the NYSE Listed Company Manual relating to minimum market capitalization and stockholders' equity. In the Acceptance Letter, the NYSE granted the Company an 18-month period from September 12, 2024 (the "Plan Period") to regain compliance with the continued listing standards. As part of the Plan, the Company is required to provide the NYSE quarterly updates regarding its progress towards the goals and initiatives in the Plan. In the Plan, Kore included details regarding previously reported operational restructuring activities, as well as an outlook on the Company's business.&nbsp;

KORE

KORE Announces NYSE Granted The Company An 18-Month Period From September 12, 2024 To Regain Compliance With The Continued Listing Standards

Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) has outperformed the market over the past 10 years by 1.8% on an annualized basis producing an average annual return of 12.9%. Currently, Guidewire Software has a market capitalization of $14.36 billion. 
Buying $100 In GWRE: If an investor had bought $100 of GWRE stock 10 years ago, it would be worth $333.15 today based on a price of $173.74 for GWRE at the time of writing.
<h3>Guidewire Software's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734991208_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GWRE

Here's How Much $100 Invested In Guidewire Software 10 Years Ago Would Be Worth Today

Company Priorities for 2025
Looking at both the improvements in the base business and the advances we made with vagus nerve stimulation (VNS), we have a lot to be proud of in 2024.
I am even more pleased we accomplished all of this while slashing our net operating loss by more than 30%.
As we look to 2025,
<ul>
<li>We are exploring new opportunities to increase cash flow generated by the ClearUP business.</li>
<li>We look forward to completing the current work with Feinstein Institute of Bioelectronic Medicine.</li>
<li>We are charting disease-specific clinical trials, moving the company closer to securing regulatory approvals for what we expect will be life-changing treatments for patients in need.</li>
<li>We look forward to talking in more detail about the specific target indications as we advance into the next stage of clinical trial work in 2025.</li>
</ul>
We anticipate that the advancement of our clinical programs for ncVNS will be key to increasing long-term shareholder value. In addition, the board and I continue to evaluate a range of options to maximize shareholder returns, including taking the necessary steps to ensure we regain Nasdaq listing compliance.
I would like to recognize the exceptional efforts of the lean and dedicated Tivic Health team. I thank them for their relentless drive and hard work. Together, with our investors, collaborators, and supporters, we are striving to build a company that can transform the future of medicine and make a lasting, positive impact on the lives of people around the world.
We are excited about the opportunities that lie ahead, and we look forward to continuing this journey with all of you in 2025.
Sincerely,
Jennifer Ernst Chief Executive Officer

Guidance

TIVC

Tivic Health CEO Outlines 2025 Priorities, Sees 30% Reduction in Net Operating Loss, ClearUP Cash Flow Initiatives, ncVNS Clinical Programs To Boost Shareholder Value, Collaboration With Feinstein Institute, And Plans For Nasdaq Compliance

On Sunday, Jeff Bezos, founder of Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), denied rumors that he has planned a $600 million wedding to marry his fiancée, Lauren Sanchez. Bezos and several other celebrities reacted to the since-debunked<a href="https://www.benzinga.com/general/entertainment/24/12/42639012/inside-jeff-bezos-600m-wedding-to-lauren-sanchez-luxe-decor-stars-and-romance"> report on social media.</a>&nbsp;&nbsp;
What To Know: The Bezos wedding rumor originated on Saturday with <a href="https://www.dailymail.co.uk/news/article-14217859/Jeff-Bezos-Lauren-Sanchez-wedding-plan-Aspen-date-is.html">a report</a> from the Daily Mail alleging the couple would marry in a $600 million dollar ceremony at Kevin Costner&#8217;s Dunbar Ranch in Aspen.&nbsp;&nbsp;
Other media outlets picked up the story and billionaire investor Bill Ackman questioned the validity of the report in a response to a story from the NY Post.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is not credible. Unless you are buying each of your guests a house, you can't spend this much money. <a href="https://t.co/1TVGOBLe9D">https://t.co/1TVGOBLe9D</a>
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1870814198898258422?ref_src=twsrc%5Etfw">December 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next: <a href="https://www.benzinga.com/24/12/42653466/honda-nissan-plan-to-merge-in-the-face-of-chinese-ev-competition">Honda, Nissan Confirm Merger Plans To Offset Chinese EV Competition: How Mitsubishi Factors In</a>
Bezos then responded to Ackman's post with a full denial of the rumored wedding.&nbsp;
&#8216;This whole thing is completely false &#8211; none of this is happening,&#8217; he posted on X. &#8216;The old adage &#8220;don&#8217;t believe everything you read&#8221; is even more true today than it ever has been.&#8217;
&#8216;Now lies can get ALL the way around the world before the truth can get its pants on. So be careful out there folks and don&#8217;t be gullible,&#8217; Bezos said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Furthermore, this whole thing is completely false — none of this is happening. The old adage "don't believe everything you read" is even more true today than it ever has been. Now lies can get ALL the way around the world before the truth can get its pants on. So be careful out… <a href="https://t.co/wz2SWp6wBZ">https://t.co/wz2SWp6wBZ</a>
&mdash; Jeff Bezos (@JeffBezos) <a href="https://twitter.com/JeffBezos/status/1870833626079752672?ref_src=twsrc%5Etfw">December 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Elon Musk, currently the richest man in the world, also responded to the social media thread with well-wishes for his rival. Musk said that &#8220;even if one is not present,&#8221; he hopes Bezos holds &#8220;an epic wedding&#8221; in the future. 
Bezos is currently the second-richest man in the world, <a href="https://www.bloomberg.com/billionaires/">according </a>to Bloomberg, and the men have battled for first place in the past. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">That said, I hope you do hold an epic wedding. It's nice to know that epic events are happening somewhere in the world, even if one is not present. A world where there are amazing events somewhere is better than a world where they are happening nowhere.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1870884997848281263?ref_src=twsrc%5Etfw">December 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Michael Saylor, chairman of MicroStrategy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) and outspoken Bitcoin advocate, also responded to Bezos' denial of the $600 million wedding rumors.&nbsp;
"$600M would buy a lot of Bitcoin," Saylor posted.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">$600M would buy a lot of Bitcoin.
&mdash; Michael Saylor&#x26a1;&#xFE0F; (@saylor) <a href="https://twitter.com/saylor/status/1870855350372749702?ref_src=twsrc%5Etfw">December 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
What Else: Though Bezos denied rumors of an upcoming Aspen nuptial, he did not give any details about when or where a wedding may take place for the couple. Bezos, 60, and Sanchez, 55, have been engaged since May 2023 and have remained relatively tight-lipped regarding their wedding plans.&nbsp;
&#8220;We're still thinking about the wedding,&#8221; Sanchez told<a href="https://www.vogue.com/article/lauren-sanchez-december-2023-interview-profile"> Vogue</a> in November 2023.
&#8220;What it's going to be. Is it going to be big? Is it going to be overseas? We don't know yet. We've only been engaged five months!&#8221; she said. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/12/42598651/mystery-drone-sightings-all-over-the-country-trump-says-what-to-know-about-investigations-lawmakers-reactions">&#8216;Mystery Drone&#8217; Sightings Spark Investigations, Politicians Respond: &#8216;Shoot Them Down,&#8217; Trump Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

MSTR

Jeff Bezos Says $600 Million Wedding Rumor Is 'Completely False': Elon Musk, Michael Saylor, Bill Ackman Respond

NAAS

NaaS Technology Entered Into Share Subscription Facility Agreement With Certain Investors For Purchase And Sale Of Up To $15M American Depositary Shares

<a href="https://www.globenewswire.com/Tracker?data=iEsbPOu_RraGf7-WB21CvqAYpPZtVKoYd3mBRubaWzkcBxwToK9z1m2epCg4WSoJAyKW4p46GjjDmk8h0FxkOYineJd8ayb72rcdOAfYUrw=">Hyperscale Data, Inc.</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#NYSE">GPUS</a>), a diversified holding company ("Hyperscale Data" or the "Company"), announced that it was notified today by the NYSE American that due to the Company's disclosure in its Form 10-Q filed for the fiscal period ended September 30, 2024, which reported stockholders' equity of approximately $2.2 million, it no longer meets the requirement that it must have no less than $6 million or more in stockholders' equity pursuant to the listing standard set forth under Section 1003(a)(ii) and (iii) of the NYSE American Company Guide (the "Listing Standards") because the Company has reported losses from continuing operations and/or net losses in five of its most recent fiscal years ended December 31, 2023.

GPUS

Hyperscale Data Receives Notice Of Noncompliance With NYSE American Listing Standards

FirstCash Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCFS#NASDAQ">FCFS</a>) has outperformed the market over the past 20 years by 2.46% on an annualized basis producing an average annual return of 10.74%. Currently, FirstCash Hldgs has a market capitalization of $4.61 billion. 
Buying $100 In FCFS: If an investor had bought $100 of FCFS stock 20 years ago, it would be worth $768.79 today based on a price of $102.98 for FCFS at the time of writing.
<h3>FirstCash Hldgs's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734990314_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FCFS

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

After a solid first-quarter earnings report, Vertex Pharmaceuticals (VRTX) comfortably topped analysts' earnings and revenue estimates in the first quarter. But should investors consider adding the stock to their portfolio now? Let's look at its financial metrics to gauge its prospects… On May 6, 2024, Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>), a pharmaceutical company pioneering in the field of Cystic Fibrosis (CF), reported solid first-quarter results as the company saw progress in its R&amp;D pipeline. Its net product revenues increased 13.3% year-over-year to $2.69 billion, while its non-GAAP <a href="https://www.investopedia.com/terms/o/operatingearnings.asp">operating income</a> surged 48.1% from the prior-year quarter to $1.34 billion.
Additionally, its non-GAAP net income came in at $1.24 billion or $4.76 per common share, representing more than a 56% year-over-year increase. However, as of March 31, 2024, VRTX's cash and cash equivalents and marketable securities amounted to $10.17 billion, down from $11.22 billion as of December 31, 2023.
Moreover, the company comprehensively surpassed Wall Street's EPS and revenue estimates. For the first quarter, VRTX's earnings per share was 17.2% above the consensus estimate, and its revenue was 4.3% higher than the analysts' estimates. It is no surprise that VRTX's strong earnings have topped the EPS estimates in each of the past consecutive four quarters.
Shares of VRTX have gained 18.8% over the past nine months and 17.9% over the past year to close the last trading session at $410.24.
Here are the fundamental aspects of VRTX that could influence its price performance in the near term:
Positive Developments
Last month, the company entered into a definitive agreement to acquire Alpine Immune Sciences, Inc. (<a href="https://stocknews.com/stock/ALPN/">ALPN</a>) for approximately $4.9 billion in cash. This deal includes obtaining povetacicept, a Phase 3-ready asset known for its potential in treating IgA nephropathy and its status as a potential pipeline-in-a-product.
VRTX's CEO, Reshma Kewalramani, views the acquisition as strategically advantageous, as it aligns with The company's mission to address unmet needs in specialty markets. Further, this move aims to integrate ALPN's protein engineering and immunotherapy capabilities into the VRTX's portfolio.
On top of this, VRTX reached a clinical milestone for VX-670 in DM1 in the first quarter of 2024, triggering a $75 million milestone payable to Entrada.
Favorable Analyst Estimates
The consensus revenue estimate of $2.66 billion for the fiscal second quarter (ending June 2024) represents a 6.7% increase year-over-year. The consensus EPS estimate of $4.17 for the current quarter indicates a 7.2% improvement year-over-year. The company has an excellent surprise history, surpassing the consensus revenue estimates in three of the trailing four quarters.
VRTX's revenue and EPS for the current year (ending December 2024) are expected to grow 9% and 11.6% year-over-year to $10.75 billion and $17.02, respectively. Looking ahead, analysts forecast an 8.8% and 6.7% year-over-year growth in VRTX's revenue and EPS for fiscal year 2025, projecting figures of $11.70 billion and $18.16, respectively.
Discounted Valuation
In terms of forward non-GAAP PEG, VRTX is currently trading at 0.75x, 60.5% lower than the industry average of 1.89x. Its forward P/E multiple of 26.19 is 4.5% lower than the industry average of 27.53x.
In addition, the stock's trailing-12-month EV/EBIT of 20.50x is 9.6% lower than the 23.18x industry average.
Robust Profitability
VRTX's trailing-12-month EBITDA margin of 44.87% is 728.8% higher than the 5.41% industry average. The stock's trailing-12-month levered FCF margin of 35.57% is significantly higher than the 0.53% industry average.
Further, its trailing-12-month net income margin, ROCE, and ROTA of 39.46%, 24.38%, and 16.81% compares to the negative industry averages of 5.52%, 40.87%, and 29.54%, respectively.
POWR Ratings Exhibit Solid Prospects
VRTX's solid outlook is reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to Buy in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories.
VRTX boasts a B grade for Value, mirroring its discounted valuation. Additionally, it also earns a B for Quality, reflecting its superior profitability metrics compared to industry standards.
The stock is ranked #8 out of 359 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. <a href="https://stocknews.com/stock/VRTX/">Click here</a> to access VRTX's Growth, Momentum, Stability, and Sentiment ratings.
Bottom Line
VRTX kicked off the year on a strong note, with sharp increases in profits and revenue in the first quarter, primarily fueled by the robust uptake of Trikafta among younger patients. Moreover, the anticipation of regulatory approvals for VRTX's therapies across various global regions signals a promising outlook for the company's expansion and market reach.
Additionally, the company's reaffirmed revenue guidance for fiscal year 2024 (total product revenues are expected to range from $10.55 billion to $10.75 billion) reflects a confident outlook for sustained growth in the cystic fibrosis sector, alongside the potential introduction of Casgevy in new indications and markets.
Plus, the activation of treatment centers for Casgevy and the collection of cells from patients for its commercial launch in sickle cell disease and transfusion-dependent Beta-thalassemia are some promising developments.
Given these factors, coupled with robust profitability, optimistic analyst estimates, and discounted valuation underscore the company's strong financial position and the potential for future earnings growth.
Hence, we believe that investing in this stock could help you garner substantial returns.
How does Vertex Pharmaceuticals Incorporated (VRTX) Stack Up Against its Peers?
Other stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> sector that may be worth considering are Sino Biopharmaceutical Limited (<a href="https://stocknews.com/stock/SBHMY/">SBHMY</a>), Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>), and Otsuka Holdings Co., Ltd. (<a href="https://stocknews.com/stock/OTSKY/">OTSKY</a>) - they have an overall rating of A (Strong Buy). <a href="https://stocknews.com/category/biotech/">Click here</a> to explore more Biotech stocks.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
VRTX shares were trading at $423.48 per share on Wednesday afternoon, up $13.24 (+3.23%). Year-to-date, VRTX has gained 4.08%, versus a 9.10% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/vrtx-sbhmy-gild-otsky-alpn-vertex-pharmaceuticals-vrtx-earnings-review-is-it-time-to-buy/>Vertex Pharmaceuticals (VRTX) Earnings Review: Is it Time to Buy?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Vertex Pharmaceuticals (VRTX) Earnings Review: Is it Time to Buy?

Sino Biopharmaceutical Limited goes ex dividend tomorrow

Given Organogenesis's (ORGO) upbeat first-quarter results and promising development of its ReNu program for knee osteoarthritis, the company seems to be on the brink of significant growth. Let's delve into its fundamentals to determine whether it's a hidden gem in the biotech sector. Read more to find out… Leading wound care specialist Organogenesis Holdings Inc. (<a href="https://stocknews.com/stock/ORGO/">ORGO</a>) surpassed Wall Street's expectations in the first quarter of fiscal 2024. The company reported revenue of $109.98 million, well above the analysts' estimate of $100.23 million. This figure also outpaced their guidance, which projected revenue between $98 million and $104 million, driven by a surge in momentum from February into March.
Building on the momentum, Organogenesis forecasts positive growth for the year ending December 31, 2024. The company expects net revenue to range between $445 million and $470 million, marking a year-over-year increase of 3% to 9% compared to the $433.1 million reported for 2023. However, the profitability outlook is mixed, with expected adjusted <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> (loss) ranging from ($8.1) million to $7.1 million and adjusted EBITDA between $15.8 million and $35.0 million.
While revenue growth is strong, Organogenesis has been experiencing an unsettling string of earnings contractions, which could pose a challenge in the near term. ORGO's net loss per share was $0.02, compared to the consensus estimate of 0.03.
Shares of ORGO have gained 1.5% over the past month to close the last trading session at $2.70. However, the stock has plunged 21.9% over the past year and 33.7% year-to-date.
Let's look at factors that could influence ORGO's performance in the upcoming months.
Promising Progress in ReNu Phase III Clinical Trials
Organogenesis has made notable progress with its ReNu program, which aims to manage knee osteoarthritis (OA) symptoms. Recently, the company shared<a href="https://investors.organogenesis.com/news-releases/news-release-details/organogenesis-achieves-primary-endpoint-phase-3-clinical-trial"> positive top-line results</a> from its first Phase III clinical trial, achieving the primary endpoint with a p-value of 0.0177. The trial demonstrated a significant reduction in knee OA pain over six months compared to a saline control group.
By 2027, an estimated 34.4 million Americans will be affected by knee OA. ReNu could offer a non-surgical pain management option, particularly for the most severe cases, representing around 5 million people. If approved, ReNu would be the only FDA-approved biologic intra-articular injection for this purpose, marking a significant advancement in the treatment of knee OA.
Mixed Financial Performance
For the first quarter that ended March 31, 2024, ORGO's net revenues increased 2.2% year-over-year to $109.98 million. Revenue from Advanced Wound Care rose 3% from the prior year to $103.9 million, while the net revenue for Surgical and Sports Medicine products was $6.1 million, down 9% year-over-year. Its gross profit grew marginally from the year-ago value to $81.28 million.
ORGO's loss from operations narrowed 3.7% from the previous year's quarter to $3.85 million. The company's net loss came in at $2.10 million compared to $2.97 million last year, while its net loss per share remained flat year-over-year at $0.02. However, ORGO recorded an adjusted EBITDA of $2.55 million in the same quarter.
As of March 31, 2024, Organogenesis' cash and cash equivalents stood at $88.63 million, compared to $103.84 million as of December 31, 2023.
Mixed Analyst Estimates
Analysts expect ORGO's EPS to increase 5.7% year-over-year to $114.73 million for the third quarter ending September 2024. For the fiscal year ending December 2024, its revenue is expected to reach $453.76 million, registering a year-over-year growth of 4.8%.
However, the company is estimated to post a loss per share of $0.01 in the current quarter and remain negative for the fiscal year 2024. Nonetheless, ORGO has an impressive earnings surprise history, surpassing the consensus EPS estimates in three of the trailing four quarters.
Discounted Valuation
In terms of forward EV/Sales, ORGO is trading at 0.88x, which is 74.2% lower than the industry average of 3.42x. Similarly, the stock's forward Price/Sales multiple of 0.82 is 76.9% lower than the industry average of 3.54x. Additionally, the stock's 2.64x forward Price/Book is 1.2% below the industry average of 2.67x.
POWR Ratings Reflect Uncertainty
ORGO's mixed fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of C, which translates to Neutral in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. ORGO has an A grade in Value, which aligns with its lower-than-industry valuation. However, with a five-year beta of 1.66, the stock has earned a grade C for Stability.
Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, ORGO is ranked #47 out of 342 stocks.
Beyond what I have stated above, we have also given ORGO grades for Growth, Momentum, Sentiment, and Quality. Get all ORGO ratings <a href="https://stocknews.com/stock/ORGO/">here</a>.
Bottom Line
Organogenesis is an anomaly among small biotechs, achieving modest revenues despite inconsistent earnings and a promising catalyst in ReNu. However, this inconsistency in earnings has proven to be a significant stumbling block. While optimism about its long-term potential is contingent upon securing FDA approval for ReNu, recent mixed financial performance and an uncertain near-term outlook raise concerns.
Given these uncertainties and the volatility typically associated with biotech investments, waiting for a better entry point in this stock seems wise now.
How Does Organogenesis Holdings Inc. (ORGO) Stack Up Against Its Peers?
Given its near-term uncertain prospects, the odds of ORGO outperforming in the weeks and months ahead are compromised. However, there are many industry peers with much more impressive POWR Ratings. So, consider these three A (Strong Buy) stocks from the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>), Nippon Shinyaku Co., Ltd. (<a href="https://stocknews.com/stock/NPPNY/">NPPNY</a>), and Sino Biopharmaceutical Limited (<a href="https://stocknews.com/stock/SBHMY/">SBHMY</a>).
To explore more A and B-rated biotech stocks, <a href="https://stocknews.com/category/biotech/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ORGO shares were trading at $2.74 per share on Monday afternoon, down $0.06 (-2.14%). Year-to-date, ORGO has declined -33.01%, versus a 15.51% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/orgo-gild-nppny-sbhmy-is-organogenesis-a-hidden-gem-in-the-biotech-sector/>Is Organogenesis a Hidden Gem in the Biotech Sector?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Is Organogenesis a Hidden Gem in the Biotech Sector?

Comments

Sino Biopharmaceutical

News

Latest news for Sino Biopharmaceutical (OTC:SBHMY) Stock

Friday, January 17, 2020

Friday, August 23, 2019

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga